NCT00322374View on ClinicalTrials.gov

Phase I Combination w/ Epirubicin

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Ixabepilone

Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.

DRUG

Epirubicin

Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².

Trial Locations (2)

20133

Local Institution, Milan

31052

Local Institution, Toulouse

Sponsors

Lead Sponsor

R-Pharm
All Listed Sponsors
lead

R-Pharm

INDUSTRY